The Retinoic Acid Receptor Alpha pipeline drugs market research report outlays comprehensive information on the Retinoic Acid Receptor Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Retinoic Acid Receptor Alpha pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Respiratory, Dermatology, and Central Nervous System which include the indications Multiple Myeloma (Kahler Disease), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bronchopulmonary Dysplasia, Idiopathic Pulmonary Fibrosis, Acne Vulgaris, Hand Dermatitis, Amyotrophic Lateral Sclerosis, and Batten Disease. It also reviews key players involved in Retinoic Acid Receptor Alpha targeted therapeutics development with respective active and dormant or discontinued products.
The Retinoic Acid Receptor Alpha pipeline targets constitutes close to 16 molecules. Out of which, approximately 16 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 2, 2, 6, and 2 respectively.
Retinoic Acid Receptor Alpha overview
Retinoic acid receptor alpha (RARA) is a nuclear receptor that is encoded by the RARA gene. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. It promotes the survival and development of early meiotic prophase spermatocytes. It regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5 and mediates retinoic acid-induced granulopoiesis.
For a complete picture of Retinoic Acid Receptor Alpha’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
